CAJ | 학술논문

目的探讨泛福舒对支气管哮喘患者诱导痰中分泌型免疫球蛋白 A（secretory immunoglobulin A，SIgA）含量的影响。方法将我院诊治的病历资料完整的60例哮喘患者随机分成观察组、对照组各30例，两组患者在给予常规治疗的基础上，对照组给予沙美特罗丙酸氟替卡松粉吸入剂(50/250μg)吸入，1吸/次，2次/d；观察组在给予上述治疗的基础上再加用泛褔舒治疗，7 mg/次，1次/d，1疗程10d，停20d，再进行第2疗程。结果与治疗前比较，两组患者治疗后痰中 SIgA含量均降低，差异有统计学意义(P<0.05)；治疗后两组患者间诱导痰中SIgA含量比较，差异显著(P<0.05)；与治疗前比较，两组患者治疗后肺功能 FEV1/FVC值均上升，差异有统计学意义(P<0.05)，而治疗后两组间比较，差异无统计学意义(P>0.05)；与治疗前相比，两组患者后FEV1/预计值较治疗前上升，差异有统计学意义(P<0.05)；而治疗后两组间比较，差异无统计学意义(P>0.05)。结论口服泛福舒治疗支气管哮喘，可以减轻支气管局部SIgA下降的程度，而对哮喘患者的肺功能无不良影响。
목적탐토범복서대지기관효천환자유도담중분비형면역구단백 A（secretory immunoglobulin A，SIgA）함량적영향。방법장아원진치적병력자료완정적60례효천환자수궤분성관찰조、대조조각30례，량조환자재급여상규치료적기출상，대조조급여사미특라병산불체잡송분흡입제(50/250μg)흡입，1흡/차，2차/d；관찰조재급여상술치료적기출상재가용범부서치료，7 mg/차，1차/d，1료정10d，정20d，재진행제2료정。결과여치료전비교，량조환자치료후담중 SIgA함량균강저，차이유통계학의의(P<0.05)；치료후량조환자간유도담중SIgA함량비교，차이현저(P<0.05)；여치료전비교，량조환자치료후폐공능 FEV1/FVC치균상승，차이유통계학의의(P<0.05)，이치료후량조간비교，차이무통계학의의(P>0.05)；여치료전상비，량조환자후FEV1/예계치교치료전상승，차이유통계학의의(P<0.05)；이치료후량조간비교，차이무통계학의의(P>0.05)。결론구복범복서치료지기관효천，가이감경지기관국부SIgA하강적정도，이대효천환자적폐공능무불량영향。
Objective To investigate the impact of Broncho-vaxom to SIgA content of induced sputum of bronchial asthma patients.Methods 60 cases with asthma diagnosed and treated in our hospital with complete medical records were randomly divided into observation group and control group (30,30 cases) , two groups of patients were given conventional treatment is the basis, and the control group were treated with salmeterol-fluticasone propionate (50 /250μg ), each suction, 2 times / d; the observation group were given on the basis of the above treatment combined with broncho-vaxom, 7mg qd, a course of 10 days, after a interval of 20 days and then a second course. Detected SIgA in induced sputum by ELISA, lung function with a spirometer testing patients prior and post treatment, to observe SIgA changes of the induced sputum and lung function in the patient.Results Compared with post treatment, pre-therapy of the two groups of SIgA of sputum were lower, the dif erence between the two groups of patients was statistical y significant (P<0.05); after treatment,the SIgA of induced sputum were significant dif erence (P<0.05); Compared with pre-therapy, post-treat the FEV1/FVC values of lung function of the two groups of patients both rise, the dif erences were significant (P<0.05) ;after treatment,the dif erence between the two groups was not statistical y significant (P>0.05);Compared with pre-therapy, post-treat FEV1/predictive values of the two groups of patients both rose, the dif erence were significant (P<0.05); The dif erence between the two groups was not statistical y significant (P>0.05).Conclusion Oral broncho-vaxom to treat bronchial asthma can mitigate the decline of the degree of SIgA in bronchial, and no adverse ef ects on lung function in patients with asthma.